The European Organisation for Research and Treatment of Cancer recommends G-CSF prophylaxis for patients undergoing a chemotherapy regimen with a high (≥ 20%) risk of febrile neutropenia and for patients receiving a chemotherapy regimen with an intermediate (10–20%) risk of febrile neutropenia if they have additional risk factors [7]. The gene discussed is CSF3; the disease is cancer.